FDA Approves Nelarabine Injection for T-ALL, T-LBL

The US Food and Drug Administration (FDA) has approved nelarabine injection for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).

The approval of the treatment provides patients with an alternative to a product that has historically been in shortage, according to Shorla Oncology, the manufacturer of the drug.

The company noted that in press release that the injection is a critical treatment for patients living with T-cell leukemia, particularly children with leukemia, and that it hoped the FDA’s approval addressed the clinical need in these patients.

Source: Shorla Oncology, March 2023